The highest contract improvement and manufacturing organizations (CDMOs) have been busy in latest months increasing their service choices, constructing new amenities, and navigating how one can incorporate synthetic intelligence (AI) into their operations. Following is a roundup of latest exercise by 5 CDMOs, based mostly on latest interviews with GEN:
Fujifilm Biotechnologies
Fujifilm Biotechnologies has celebrated the choice of its commercial-scale cell tradition manufacturing facility in Holly Springs, NC, amongst seven amenities chosen by the FDA for its PreCheck Pilot Program, designed to strengthen the nation’s pharmaceutical manufacturing capabilities.
Final 12 months, Fujifilm Biotechnologies opened the primary part of its $3.2 billion end-to-end biomanufacturing facility in Holly Springs. The corporate initially dedicated $2 billion to a facility consisting of eight 20,000 L mammalian cell tradition bioreactors, then in 2024 introduced plans to take a position an extra $1.2 billion by constructing eight extra 20,000 L bioreactors on the web site by 2028. About 800 individuals are based mostly at Holly Springs, a determine set to develop to 1,400 when the second part is accomplished.
One biopharma buyer has been introduced for the second part—the immunology drug developer argenx, which has agreed to fabricate drug substance for efgartigimod alfa-fcab marketed as intravenous Vyvgart® and mixed with hyaluronidase-qvfc as injectable Vyvgart Hytrulo®, each indicated for adults with generalized myasthenia gravis or continual inflammatory demyelinating polyneuropathy.
Holly Springs is one in every of Fujifilm Biotechnologies’ two large-scale biomanufacturing amenities. The opposite is Hillerød, Denmark, the place in April the corporate minimize a ceremonial ribbon to mark the opening of a 2,000‑sq.‑meter (21,528-square-foot) high quality management (QC) laboratory at its business‑scale manufacturing web site.
Roughly 100 members of the corporate’s High quality crew are based mostly on the lab, the place they conduct viral security testing for drug substance/product launch, scale capability for complicated cell‑based mostly efficiency and ELISA strategies, and carry out uncooked materials and significant complete natural carbon cleanability research. The QC lab additionally consists of robotics and helps the implementation of an ongoing laboratory info administration system (LIMS) throughout firm websites to allow digital harmonization and information integrity.
Operations started in Could on the QC lab, which is housed inside a brand new 7,600-square-meter (81,806-square-foot) constructing with worker facilities, workplace and collaboration house, utility companies, and an emergency generator to make sure uninterrupted operations and well timed supply of take a look at outcomes. The Hillerød web site—which mother or father firm Fujifilm Corp. acquired from Biogen in 2019 for $890 million—was expanded in 2024 from 6 to 12 x 20,000 L mammalian cell tradition bioreactors, growing the complexity and quantity for QC testing.
“Merely, we would have liked extra QC analytical capacities to help all of the elevated variety of batches and the elevated variety of testing packages,” Toshihisa Iida, director, company vp, common supervisor of Life Sciences Technique Headquarters and the Bio CDMO Division of Fujifilm, advised GEN.
“Our present focus is to get all our amenities on-line, go stay, and give attention to operational excellence as a result of we have already got huge contracts with huge shoppers. Our mission is to ship as promised,” Iida stated. “Earlier than we resolve on any next-phase funding, we’ll actually give attention to investing extra in our folks, investing extra in our high quality system, getting first-class operations, then delivering to our shoppers.”
Fujifilm Biotechnologies is a part of the Fujifilm Life Sciences Group together with Fujifilm Biosciences (previously Fujifilm Irvine Scientific), a supplier of services from discovery analysis by means of large-scale manufacturing—and three different firms, one in every of which is Fujifilm Mobile Dynamics, a developer and producer of human induced pluripotent stem cells (iPSCs) utilized in drug discovery, toxicity testing, stem cell banking, and cell remedy improvement.
In Could, Fujifilm Mobile Dynamics celebrated the opening of its new 175,000-square-foot headquarters and iPSC improvement and manufacturing facility in Madison, WI, which options cell tradition manufacturing laboratories, course of improvement laboratories, and a middle of excellence for gene enhancing—all designed to help each research-grade iPSC merchandise and improvement companies for companions growing next-generation cell therapies. The almost 200-employee facility is a part of a beforehand introduced $200 million strategic funding by Fujifilm.
Lonza Group
As AI reshapes how medicine are found, developed, clinically studied, and commercialized, Lonza Group says its operations are evolving to mirror that change. Lonza is within the strategy of constructing a crew of 20 to 30 AI-focused professionals that faucet into the CDMO’s expertise stretching again to the early Nineteen Eighties of serving to clients launch greater than 80 medicine.
“There may be retained experience that clients come to us for, and what I’m enthusiastic about is that we must always use AI to reinforce that,” Matthew Moorcroft, PhD, Lonza’s chief intelligence and analytics officer and head of the CEO workplace, advised GEN. “What we’ve discovered over the past almost 45 years is in our DNA, and it’s in our folks. Utilizing AI to additional improve that additional empowers us to do higher product launches, to serve clients faster, and to work together with them in higher methods. That’s our ambition.”
Prospects have proven curiosity, he stated, in incorporating AI into molecule discovery and designing molecules, in addition to into their scientific trial processes.
Along with strengthening its AI capabilities, Lonza is enhancing its two main operational amenities in Switzerland. The corporate introduced plans to broaden its aseptic drug product capability in Stein by including one other commercial-scale multi-purpose filling line for antibody-drug conjugates (ADCs), anticipated to be operational in 2030. The Stein growth is supported by a long-term collaboration settlement with an undisclosed “main pharmaceutical” firm for scientific and business ADC provide. Additionally at Stein, Lonza is increasing its business capabilities to high-value small molecule drug merchandise, with these operations anticipated to begin in 2028.
In June, Lonza additionally revealed plans to broaden its Visp web site to determine new commercial-scale capabilities for manufacturing extremely potent lively pharmaceutical elements (HPAPI) and ADC payload-linkers, reinforcing Lonza’s place as a completely built-in CDMO associate in ADC improvement. Lonza says the expanded Visp facility—set to be totally operational in 2028—will be capable to supply extra payload-linker manufacturing and purification alongside devoted analytical and course of improvement labs.
Past amenities, Lonza Group is reworking right into a pure-play CDMO, asserting plans in March to promote its Capsules & Well being Elements (CHI) enterprise to Lone Star Funds for CHF 2.3 billion (2.836 billion), a sale anticipated to shut earlier than 12 months’s finish. The deal—set to shut within the second half—will give Lonza CHF 1.7 billion ($2.2 billion) upfront, and a 40% stake in CHI—which completed the primary half of 2026 with core earnings earlier than curiosity, taxes, depreciation, and amortization (EBITDA) of CHF 1.152 billion ($1.42 billion) on income of CHF 3.374 billion ($4.16 billion), up 11% year-over-year.
As soon as the deal closes, Lonza says it plans to take a position its upfront proceeds into growth-focused exercise reflecting its “One Lonza” technique, which simplified operations from three divisions and 9 enterprise models into three built-in CDMO enterprise platforms (Built-in Biologics, Superior Synthesis, and Specialised Modalities), in addition to fund acquisitions of smaller complementary or “bolt-on” companies. By means of a share buyback program, Lonza plans to return CHF 500 million ($616 million) to shareholders.
“What we’ve agreed and what we’ve determined is to be purely centered on delivering worth to our CDMO clients. That’s the place Lonza’s expertise is; that’s what we do,” Moorcroft defined. “Once we did our organizational evaluation two years in the past, we requested, ‘What’s non-core to that imaginative and prescient, by way of our imaginative and prescient, function, and values?’ And being a contract producer for our clients—not making our personal merchandise, not competing with them—was truly core to what we believed in. And we imagine that pure play focus is de facto vital to maintain successful enterprise and to persuade our clients to stick with us. There’s no distraction.”
MilliporeSigma (Merck KGaA, Darmstadt, Germany)
Merck KGaA, Darmstadt, Germany, whose Life Sciences enterprise in the USA and Canada is called MilliporeSigma, is finishing building of a €300 million ($346.5 million) Bioprocessing Manufacturing Heart in Daejeon, South Korea, that’s set to open by 12 months’s finish.
“Since COVID-19, we’ve applied a world manufacturing region-for-region technique the place we’re constructing manufacturing capability in each geography, on each continent. And we proceed to try this,” Sebastián Arana, the top of Course of Options for the Life Science enterprise of Merck KGaA, Darmstadt, Germany, advised GEN.
Over the previous 4 to 5 years, Arana added, Merck KGaA’s Life Sciences enterprise has deployed greater than €3 billion ($3.465 billion) in capital expenditures (capex) towards constructing out capability to fulfill buyer demand.
In Daejeon, Arana stated Merck KGaA goals to be nearer to clients in Korea and the remainder of the Asia-Pacific area. He cited progress momentum in South Korea, fueled by enterprise exercise in addition to President Lee Jae Myung committing his authorities final 12 months to easing regulation of biotech R&D, and catapulting the nation right into a top-five biotech business powerhouse by 2030.
“Korea has deliberately invested in making a life science ecosystem in the previous couple of years,” Arana stated, “with fantastic authorities help for all times science being a important space to put money into the financial system, that’s primary. Korea is a straightforward nation to do enterprise with, so quite a lot of the Western pharma firms really feel very protected working with Korean suppliers. The entire provide chain may be very dependable, very, very fast. Plus, they’ve a historical past of excellent manufacturing capabilities and have now expanded to bioprocessing. They’re very versatile and tremendous fast—issues that pharma is in search of. They’ll do expertise transfers in months.”
One other portion of capex funding for growth of producing got here in Cork, Eire, the place Merck KGaA final 12 months opened a €150 million ($173.25 million) filtration manufacturing facility in Blarney Enterprise Park. The three,000-square-meter (32,292-square-foot) cleanroom facility was designed to help international demand for filtration merchandise used within the manufacturing of vaccines and therapies, together with monoclonal antibodies, and rising modalities resembling cell and gene therapies.
“An increasing number of, clients are asking for provide chain resiliency, redundancy, to be sure that if one thing occurs with their provide chain, they’re prepared to leap from one aspect to the opposite. That’s the elemental technique we’re executing,” Arana stated. “Ideally, they need the closest web site for them, but additionally, we attempt to have a second or perhaps a third web site certified in case one thing occurs.”
One other issue driving elevated enterprise for Merck KGaA is ongoing reshoring efforts by U.S.-based biopharmas which can be shifting extra manufacturing to the USA, whether or not to fulfill rising Stateside buyer demand, or to keep away from tariffs from the administration of President Donald J. Trump, or each.
“We see some good traction in our U.S. enterprise with clients feeling fairly good concerning the subsequent two years,” Arana stated. “It’s not modality-driven. It’s extra simply international expansion-driven, and also you see a number of the giant molecules proceed to develop and be manufactured in the USA. And on prime of that, you’ll want to suppose that the biopharma house is rising. So, there’s a pure funding that ought to come yearly simply to maintain up the worldwide demand.”
Merck KGaA expects that demand to proceed to develop: “We see the market rising within the 8 to 10% vary within the coming years,” Arana stated, citing what he known as a particularly wholesome marketplace for bioproduction of pipeline molecules by drug builders. “MilliporeSigma may be very nicely positioned to proceed to develop above market or within the higher aspect of the vary.”
Samsung Biologics
Samsung Biologics expanded into the USA earlier this 12 months when it accomplished its $353 million acquisition of a former GlaxoSmithKline (GSK) manufacturing web site in Rockville, MD. The Rockville web site provides two cGMP vegetation totaling 60,000 L of drug substance capability, able to supporting each scientific and business biologics manufacturing throughout a number of manufacturing scales, to Samsung Biologics’ complete international capability, which now stands at 845,000 L.
Samsung Biologics retained the workforce of greater than 500 that had labored for GSK, which took over the location when it accomplished its $3.6 billion acquisition of Human Genome Sciences in 2012.
“The Rockville facility offers us our first U.S. footprint and permits us to maneuver right into a strategic space inside the USA East Coast that’s nearer to shoppers, permitting for some extra flexibility with provide from U.S. soil,” John Gagliardi, gross sales director, key account administration with Samsung Biologics, advised GEN in a latest interview. “We additionally needed to be in a serious life science hub, which we’ve throughout the DMV [District of Columbia-Maryland-Virginia] space.”
The area, which manufacturers itself BioHealth Capital Area, ranks No. 3 in GEN’s A-Checklist of “High 10 U.S. Biopharma Clusters.”
The rest of Samsung Biologics’ capability is the 785,000 liters accessible at its Bio Campus I and II in Songdo, Incheon, South Korea, the place the corporate is headquartered. Inside Bio Campus II, Samsung Biologics will likely be collaborating with Lilly Gateway Labs (LGL) to determine an open innovation middle, a hub designed to help early-stage and rising biotechnology firms. The middle may have capability for as much as 30 firms to be collectively chosen by Lilly and Samsung Biologics, and can occupy a five-story, 125,000-square-foot facility set to be accomplished in July 2027.
Samsung Biologics has additionally secured land for BioCampus III, laying the groundwork for future capability growth to help next-generation therapies and rising modalities.
“BioCampus III is supposed to accommodate extra complicated modalities or new modalities that we’d get into exterior of mAbs [monoclonal antibodies],” Gagliardi defined. “That is meant for cell and gene therapies or peptides, relying on how the market wants form up. We are going to convey that capability to the market to assist because the biopharma business grows.”
Most not too long ago, on July 19, Samsung Biologics signaled its intent to broaden additional in the USA, in addition to throughout Europe and India, by asserting plans to amass publicly traded PolyPeptide Group, a CDMO specializing within the manufacturing of peptide-based lively pharmaceutical elements (APIs), for CHF 1.46 billion (about $1.8 billion).
Samsung Biologics stated the acquisition of PolyPeptide will allow it to broaden its capabilities past antibodies and antibody-drug conjugates (ADCs) to incorporate peptide therapeutics, whose quick progress has been fueled by a surge in international demand for weight problems remedies and continued growth of peptide-based therapies into new illness areas.
Headquartered in Baar, Switzerland, PolyPeptide has manufactured APIs for some 70 years and has produced greater than 1,000 therapeutic peptides to this point.
At CHF44.31 ($54.63) a share, Samsung Biologics’ supply represents a 40% premium to PolyPeptide’s closing worth of CHF31.65 ($39.02) on the SIX Swiss Change as of April 10, earlier than the corporate’s acquisition grew to become the topic of market hypothesis.
Samsung Biologics says its buyout of PolyPeptide is predicted to be accomplished “towards the tip of 2026,” topic to customary situations that embody house owners of a minimum of 66⅔% of PolyPeptide shares accepting the deal, regulatory approvals, publication of the supply prospectus in accordance with Swiss takeover legislation, and different situations.
PolyPeptide’s largest shareholder, representing roughly 55.65% of excellent shares (excluding treasury shares), helps the deal by means of an irrevocable tender supply, whereas the corporate’s unbiased and non-conflicted board members have unanimously endorsed the deliberate acquisition.
Thermo Fisher Scientific
Thermo Fisher Scientific says its two-year-old Accelerator™ Drug Improvement platform, a collection of expanded contract analysis group (CRO) and CDMO companies, has attracted clients in search of an end-to-end associate for companies starting from drug substance improvement and manufacturing, regardless of the modality, to packaging, labeling, distribution, and finishing up scientific trials by means of the corporate’s Scientific Analysis group.
“All of those companies throughout the similar firm assist scale back the time and complexity and convey all of the issues required for a sturdy CMC package deal that our sponsors would then submit for approval and get these efficient medicines to sufferers quicker,” Anil Kane, PhD, government director, international head of technical and scientific affairs at Thermo Fisher Scientific, advised GEN.
The corporate enhanced its means to glean insights from scientific trial information in March, when it accomplished its acquisition of Clario Holdings, a supplier of endpoint information options for scientific trials, for $8.875 billion money, plus potential extra milestone and different funds.
Thermo Fisher launched Accelerator in 2024, three years after buying the CRO PPD for $17.4 billion, and 7 years after increasing into the CDMO market by shopping for Patheon for $7.2 billion. At its Investor Day in Could, Mike Shafer, Thermo Fisher’s government vp and president of biopharma companies, provided examples of how two undisclosed clients benefited from Accelerator.
For a big U.S.-based biopharma in search of a quick business launch for its respiratory drug candidate for aggressive causes. Thermo Fisher ramped up a Part III trial by activating over 160 websites in lower than eight weeks, lowering enrollment time and the dosage timeline by greater than 50%. The opposite was a South Korean drug developer that saved 12 months of exercise by utilizing Accelerator to remove bottlenecks that included formulation points, trial design points, and regulatory alignment necessities.
“We took one thing that was delayed to accelerating it by virtually a 12 months,” Shafer stated.
In April, Thermo Fisher opened its flagship U.S. Bioprocess Design Heart (BDC) on the firm’s Plainville, MA, web site, increasing the ability to help clients in growing and scaling biologics. The brand new middle brings collectively superior bioproduction capabilities and hands-on collaboration, with the intention of serving to clients speed up course of improvement and convey therapies to sufferers quicker.
“Our clients have been asking about alternatives to develop on a small scale, inside a U.S. web site,” Kane stated. “Our Plainville web site was ideally positioned for our clients based mostly in North America to carry out experimentation within the improvement middle. We even have sterile fill-finish functionality on the Plainville web site. By combining the capabilities of bioprocessing in addition to sterile fill-finish, our clients may develop their molecule and the product, then resolve the subsequent steps of a scientific product that they will take to Part I and past.”
Thermo Fisher agreed in January to combine into its lab devices the AI expertise of Nvidia, with the intention of growing clever and more and more autonomous laboratories. The Nvidia announcement got here three months after Thermo Fisher agreed to embed OpenAI utility programming interfaces into areas starting from product improvement, service supply, buyer engagement, and operational effectivity.
“We’ve utilized AI instruments in high quality administration, high quality operations, and manufacturing. The concept right here is to convey efficiencies and scale back that turnaround time of high quality deviations, CAPA [Corrective and Preventive Action] administration, to convey efficiencies in planning, scheduling of operations, and scale back the downtime of apparatus,” Kane stated.
Thermo Fisher has but to publicly quantify the financial savings in time and value from AI purposes, although it says it has seen promising outcomes: “We are going to proceed to watch these and quantify these as we generate extra case research, as we generate extra information, as a result of that is actually of significance to us and our companions.”
